Skip to main content
Clinical Trials/NCT03718754
NCT03718754
Completed
Phase 3

En-bloc vs Conventional Resection of Primary Bladder Tumor: Prospective Randomized Multicenter Trial

David D'Andrea1 site in 1 country384 target enrollmentFebruary 28, 2019
ConditionsBladder Cancer

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Bladder Cancer
Sponsor
David D'Andrea
Enrollment
384
Locations
1
Primary Endpoint
The pathological staging assessment for eTURB compared to cTURB
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

Based on current evidence, we hypothesize that eTURB represents an improvement in the surgical management of NMIBC. The resection is more precise and complete compared to cTURB. Moreover, the quality of an en-bloc specimen, including the tumor with its adjacent bladder wall layers, allows an accurate pathological review which leads to correct risk allocation and therapy.

To answer these questions, we designed a RCT comparing eTURB with cTURB. Primary outcome of our study will be the accuracy of pathological staging assessment measured by the presence of detrusor muscle in the specimen as a surrogate parameter for quality of resection.

Registry
clinicaltrials.gov
Start Date
February 28, 2019
End Date
January 20, 2021
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
David D'Andrea
Responsible Party
Sponsor Investigator
Principal Investigator

David D'Andrea

M.D.

Medical University of Vienna

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

The pathological staging assessment for eTURB compared to cTURB

Time Frame: 4 weeks

The primary objective of the study is to assess whether eBLOC is associated with a higher rate of detrusor muscle in the pathologic specimen, compared to cTURB

Secondary Outcomes

  • Residual disease within 3 months after initial TURB(3 months)
  • Recurrence-free survival(up to 5 years)
  • Occurrence of obturator reflex(1 day)
  • Number of participants with obturator reflex(1 day)
  • Number of tumors with positive lateral and deep resection margin(4 weeks)
  • Operative time(1 day)
  • Number of participants with bladder perforation(7 days)
  • Upstaging of disease upon second look transurethral resection surgery(6 weeks)
  • Number of tumors with evaluable lateral and deep resection margin(4 weeks)
  • Number of participants with conversion to other resection technique(1 day)
  • Number of participants with persistent disease at 2nd look TURB(6 weeks)

Study Sites (1)

Loading locations...

Similar Trials